Currently, the predominant circulating variant of concern of SARS-CoV-2 is Omicron VoC and globally, the BA.2 Omicron lineage has been seen to replace the BA.1 lineage, the sources said.
A booster dose of Covaxin administered six months after the two dose primary vaccination has shown elevated immune responses against SARS-CoV-2 variants of concern including Omicron, a study by ICMR and Bharat Biotech has found.